Wolfe Research analyst Justin Lake downgraded Cano Health to Peer Perform from Outperform without a price target. The an last cites the company’s "challenging" capital position and lack of forward visibility for the downgrade. Heading into 2023, "the path forward for Cano is difficult to determine," Lake tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CANO:
- Citi opens ‘positive Catalyst Watch’ on Cano Health
- BofA resumes Cano Health at Underperform, sees potential more guidance cuts
- Cano Health resumed with an Underperform at BofA
- Third Point sold Cano Health stake last week, Bloomberg reports
- Cano Health downgraded at Cowen with liquidity ‘now a plausible 2023 concern’